
The last month of Ascendis' second quarter will be eventful for the Danish biotech company listed in the US.
On June 25 at the latest, the US Food and Drug Administration (FDA) will make a decision on Ascendic's first commercial product Transon hgh, which is also known as lonapegsomatropin. The FDA is currently assessing the drug as a treatment for children with growth hormone deficiency (GHD).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app